Cipla Ltd. — Regulatory Filings 2021

Dec 28, 2021

28[th] December 2021

(1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA EQ

• (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Press Release - Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug ® - Cipmolnu (Molnupiravir 200 mg) in India to treat mild to moderate COVID 19 at high risk of developing severe disease

Dear Sir / Madam,

Please find enclosed press release dated 28[th] December 2021 for the captioned subject.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully, For Cipla Limited

RAJENDR Digitally signed by RAJENDRA A KUMAR KUMAR CHOPRA Date: 2021.12.28 CHOPRA 12:38:15 +05'30'

Rajendra Chopra Company Secretary

Encl: as above

Prepared by: Mandar Kurghode

==> picture [114 x 62] intentionally omitted <==

Cipla receives Emergency Use Authorisation (EUA) to launch oral antiviral drug Cipmolnu® (Molnupiravir 200 mg) in India to treat mild to moderate COVID-19 at high risk of developing severe disease

Mumbai, India; December 28, 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced today that it has been granted Emergency Use Authorisation(EUA) permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir in the country. Cipla plans to launch Molnupiravir under the brand name Cipmolnu®. Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease[1] .

Earlier in the year, Cipla entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir in India and to over 100 low and middle-income countries (LMICs). The regulatory approval comes on the back of a five-month collaborative trial conducted by a consortium of companies.

Cipla will soon make Cipmolnu ® 200mg capsules available at all leading pharmacies and Covid treatment centers across the country. The Company has adequate manufacturing capacities and a solid distribution mechanism in place to ensure speedy access to this effective treatment pan India.

Commenting on the launch, Mr. Umang Vohra (MD and Global CEO, Cipla Limited) said , “This

launch is yet another step in our endeavour to enable access to all treatments in COVID care. We continue to be guided by the power of science to address the unmet needs of patients across the globe and bring care closer to the patients.

Molnupiravir is an oral anti-viral that inhibits the replication of multiple RNA viruses including SARS-CoV-2. The drug is used for the treatment of non-hospitalized patients with confirmed COVID-19 globally.

1 https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra

About Cipla :

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are wellknown. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT October 2021), 3rd largest in the pharma

==> picture [596 x 65] intentionally omitted <==

private market in South Africa (IQVIA MAT October 2021), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has

inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

==> picture [596 x 65] intentionally omitted <==